Detalhe da pesquisa
1.
Genomic characterisation of hormone receptor-positive breast cancer arising in very young women.
Ann Oncol
; 34(4): 397-409, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36709040
2.
Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer.
Ann Oncol
; 31(3): 377-386, 2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-32067679
3.
A gene signature to predict high tumor-infiltrating lymphocytes after neoadjuvant chemotherapy and outcome in patients with triple-negative breast cancer.
Ann Oncol
; 29(1): 162-169, 2018 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29077781
4.
De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017.
Ann Oncol
; 28(8): 1700-1712, 2017 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28838210
5.
A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1).
Ann Oncol
; 27(5): 812-8, 2016 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-27052658
6.
Neoadjuvant treatment with docetaxel plus lapatinib, trastuzumab, or both followed by an anthracycline-based chemotherapy in HER2-positive breast cancer: results of the randomised phase II EORTC 10054 study.
Ann Oncol
; 26(2): 325-32, 2015 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-25467016
7.
Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials).
Ann Oncol
; 26(5): 873-879, 2015 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-25725046
8.
Identification of SNPs associated with response of breast cancer patients to neoadjuvant chemotherapy in the EORTC-10994 randomized phase III trial.
Pharmacogenomics J
; 15(1): 63-8, 2015 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-24958282
9.
Pathological complete response after neoadjuvant chemotherapy is an independent predictive factor irrespective of simplified breast cancer intrinsic subtypes: a landmark and two-step approach analyses from the EORTC 10994/BIG 1-00 phase III trial.
Ann Oncol
; 25(6): 1128-36, 2014 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-24618153
10.
Symptoms of endocrine treatment and outcome in the BIG 1-98 study.
Breast Cancer Res Treat
; 143(1): 159-69, 2014 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-24305979
11.
Palbociclib combined with endocrine treatment in hormone receptor-positive, HER2-negative breast cancer patients with high relapse risk after neoadjuvant chemotherapy: subgroup analyses of premenopausal patients in PENELOPE-B.
ESMO Open
; 9(6): 103466, 2024 Jun 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-38838498
12.
Prognostic value of EndoPredict test in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative primary breast cancer screened for the randomized, double-blind, phase III UNIRAD trial.
ESMO Open
; 9(5): 103443, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38692082
13.
Reply to 'The St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017: the point of view of an International Panel of Experts in Radiation Oncology' by Kirova et al.
Ann Oncol
; 29(1): 281-282, 2018 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29045519
14.
De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017.
Ann Oncol
; 29(10): 2153, 2018 Oct 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29733336
15.
Docetaxel rechallenge after a first response in non-resistant metastatic breast cancer: significant activity with manageable toxicity.
Breast Cancer Res Treat
; 134(1): 325-32, 2012 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-22531859
16.
An immunological signature to predict outcome in patients with triple-negative breast cancer with residual disease after neoadjuvant chemotherapy.
ESMO Open
; 7(4): 100502, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35759853
17.
A review of PARP inhibitors: from bench to bedside.
Ann Oncol
; 22(2): 268-79, 2011 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-20643861
18.
A clinical case of invasive lobular breast carcinoma with ERBB2 and CDH1 mutations presenting a dramatic response to anti-HER2-directed therapy.
Ann Oncol
; 27(1): 199-200, 2016 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-26487584
19.
Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials).
Ann Oncol
; 26(12): 2505-6, 2015 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-26467471
20.
Endocrine-responsive breast cancer special types: who cares?
Ann Oncol
; 23(6): 1375-7, 2012 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-22547540